[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Immunology](https://durgical.com/en/immunology/) › [Transplant, tumors and immunotherapy](https://durgical.com/en/immunology/areas/transplant/) › Haematopoietic stem cell transplant: the immunology

# Haematopoietic stem cell transplant: the immunology

- Process

A stem cell transplant replaces the whole blood and immune system; the new immune system can fight leukaemia but can also attack the patient.

Updated Nov 15, 2026

## Key points

- Autologous = no GVHD, no GVL; allogeneic = both.
- Neutrophils engraft first; T cells recover last.
- GVL from donor T and NK cells; donor lymphocyte infusion for relapse.
- Early bacteria/fungi → CMV → late encapsulated bacteria.
- Revaccinate after transplant; live vaccines only after recovery.

## What it is

Haematopoietic stem cell transplantation (HSCT) replaces a patient’s marrow with stem cells from the patient (autologous) or a donor (allogeneic). After conditioning, donor cells engraft and rebuild every blood and immune cell. In allogeneic transplant, donor T and NK cells can kill remaining leukaemia (graft-versus-leukaemia) but can also cause [graft-versus-host disease](https://durgical.com/en/conditions/graft-versus-host-disease/), and immunity recovers slowly, shaping a predictable infection timeline.

## How to think about it

Allogeneic transplant is installing a new immune system: it brings its own soldiers, who fight the leukaemia (GVL) and may also fight the host (GVHD), two sides of the same donor T-cell attack. Autologous transplant is reinstalling your own system after intensive chemotherapy, so it has neither. Rebuilding is staged, so infections follow a timeline: neutrophils first, T cells last.

## Step by step

- Stem cells come from marrow, from blood after mobilisation with G-CSF, or from cord blood.
- Conditioning (chemotherapy ± radiation) destroys diseased marrow and suppresses host immunity so the graft is not rejected.
- Stem cells are infused into a vein and home to the bone marrow.
- Neutrophils recover first, within weeks; platelets later; chimerism studies confirm donor origin.
- NK cells return early; T cells take months to years, because thymic output is limited, especially in adults.
- Donor T and NK cells kill leukaemia (GVL) and may attack host tissues (GVHD).
- Patients are revaccinated from scratch; live vaccines wait for immune recovery without GVHD.

## Autologous vs allogeneic transplant

| Feature | Autologous | Allogeneic |
| --- | --- | --- |
| Source | The patient’s own stem cells | A donor: matched sibling, unrelated, haploidentical or cord blood |
| Main uses | Myeloma, relapsed lymphoma (allows intensive chemotherapy) | Acute leukaemias, myelodysplasia, [aplastic anaemia](https://durgical.com/en/conditions/aplastic-anaemia/), [SCID](https://durgical.com/en/pediatrics/the-child-with-recurrent-infections-normal-or-an-immune-problem/), [thalassaemia](https://durgical.com/en/conditions/thalassemias/), [sickle cell disease](https://durgical.com/en/conditions/sickle-cell-disease/) |
| GVHD | No | Yes |
| Graft-versus-leukaemia | No | Yes |
| Graft rejection | Not an issue | Possible (host T and NK cells) |

## Clinical notes

- Infection timeline: early bacteria and fungi (neutropenia, mucositis); then CMV reactivation and other viruses; late encapsulated bacteria, especially with chronic GVHD.
- EBV-driven [post-transplant lymphoproliferative disorder](https://durgical.com/en/conditions/the-solid-organ-transplant-recipient-infections-cancer-and-drug-interactions/) can occur when T cells are depleted.
- Donor lymphocyte infusion can treat relapse by boosting graft-versus-leukaemia, at the risk of GVHD.
- Reduced-intensity conditioning relies on graft-versus-leukaemia rather than on chemotherapy to cure.

## Common traps

- **Autologous transplant cures leukaemia through graft-versus-leukaemia**: it has no GVL, it only rescues the marrow after intensive chemotherapy.
- **Removing all donor T cells is ideal**: it lowers GVHD but raises relapse, [graft failure](https://durgical.com/en/conditions/skin-grafts-and-flaps-covering-a-wound/) and EBV lymphoproliferation.
- **Engraftment means the immune system is back**: neutrophils return in weeks, but T-cell immunity takes months to years.
- **Childhood vaccines still protect after allogeneic transplant**: immune memory is lost, so the patient is revaccinated from scratch.

## Test yourself

Think of the answer, then tap the question to see it.

## Why is graft-versus-leukaemia inseparable in practice from graft-versus-host disease?

Both are attacks by donor T and NK cells on recipient cells; the same alloreactivity that kills leukaemia also damages host tissues.

## Why does GVHD not occur after autologous transplant?

The stem cells and lymphocytes are the patient's own, so they recognise the host as self.

## Three months after allogeneic transplant, neutrophils are normal but CMV reactivates. Why is the patient still vulnerable?

T-cell recovery lags far behind neutrophils, and CMV control depends on T cells; GVHD prophylaxis adds to the gap.

## A patient relapses after allogeneic transplant. What immune treatment can boost GVL, and what is its risk?

Donor lymphocyte infusion; it boosts graft-versus-leukaemia but can trigger GVHD.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/immunology/haematopoietic-stem-cell-transplant-the-immunology/)

## Elsewhere in DurgiPedia

- [Hematopoiesis and bone marrow](https://durgical.com/en/histology/hematopoiesis-and-bone-marrow/)

## Connections

## Related 7

- [Graft-versus-host disease: the immunology](https://durgical.com/en/immunology/graft-versus-host-disease-the-immunology/)
- [HLA inheritance, typing and the crossmatch](https://durgical.com/en/immunology/hla-inheritance-typing-and-the-crossmatch/)
- [How grafts are recognised: direct and indirect allorecognition](https://durgical.com/en/immunology/how-grafts-are-recognised-direct-and-indirect-allorecognition/)
- [Bone marrow and hematopoiesis of immune cells](https://durgical.com/en/immunology/bone-marrow-and-hematopoiesis-of-immune-cells/)
- [Haematopoietic cytokines: G-CSF, GM-CSF, M-CSF, IL-3, IL-7](https://durgical.com/en/immunology/haematopoietic-cytokines-g-csf-gm-csf-m-csf-il-3-il-7/)
- [Treating inborn errors of immunity: IgG, transplant, gene therapy](https://durgical.com/en/immunology/treating-inborn-errors-of-immunity-igg-transplant-gene-therapy/)
- [Transplant rejection: hyperacute, acute, chronic](https://durgical.com/en/immunology/transplant-rejection-hyperacute-acute-chronic/)

## Related conditions 2

- [Acute leukaemia (AML and ALL)](https://durgical.com/en/conditions/acute-leukaemia/)
- [Sickle cell disease](https://durgical.com/en/conditions/sickle-cell-disease/)

## Microorganisms 2

- [Cytomegalovirus](https://durgical.com/en/microbiology/cytomegalovirus/)
- [Epstein–Barr virus](https://durgical.com/en/microbiology/epstein-barr-virus/)

## In Pharmacology 1

- [Filgrastim](https://durgical.com/en/pharmacology/filgrastim/)

[← All of immunology](https://durgical.com/en/immunology/)

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: [Stem Cell Transplants in Cancer Treatment](https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant) (National Cancer Institute (NIH), 2023); [Bone marrow transplant](https://medlineplus.gov/ency/article/003009.htm) (MedlinePlus, US National Library of Medicine, 2024); [Graft-versus-host disease](https://medlineplus.gov/ency/article/001309.htm) (MedlinePlus, US National Library of Medicine, 2024).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/immunology/haematopoietic-stem-cell-transplant-the-immunology/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/immunology/haematopoietic-stem-cell-transplant-the-immunology/
